US2023043663A1PendingUtilityA1

Pharmaceutical compositions comprising perillyl alcohol derivatives

Assignee: NEONC TECH INCPriority: Feb 12, 2015Filed: Sep 13, 2022Published: Feb 9, 2023
Est. expiryFeb 12, 2035(~8.6 yrs left)· nominal 20-yr term from priority
A61P 35/00C07D 487/04A61K 31/495C07D 231/12C07D 493/04C07D 493/14C07D 253/075
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating a disease or disorder in a mammal, comprising the step of administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a topiramate perillyl alcohol (POH) linoleate triple conjugate compound having a structural formula of 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein the pharmaceutical composition is administered by inhalation, intranasally, orally, intravenously, topically, transdermally, subcutaneously or intramuscularly. 
     
     
         3 . The method of  claim 1 , wherein a symptom of the disease or disorder is seizures. 
     
     
         4 . The method of  claim 1 , wherein the mammal is a human. 
     
     
         5 . A method for treating a disease or disorder in a mammal, comprising the step of administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of a lamotrigine perillyl alcohol (POH) linoleate triple conjugate compound having a structural formula of 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 1 , wherein the pharmaceutical composition is administered by inhalation, intranasally, orally, intravenously, topically, transdermally, subcutaneously or intramuscularly. 
     
     
         7 . The method of  claim 1 , wherein a symptom of the disease or disorder is seizures. 
     
     
         8 . The method of  claim 1 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2023043663A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.